TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04037969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nesofilcon A
Description: Hydrogel contact lens for daily wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nesofilcon A
Description: Hydrogel contact lens for daily wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A
Description: Silicone hydrogel contact lens for daily wear

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delefilcon A
Description: Silicone hydrogel contact lens for daily wear
Study: NCT01447212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacetylmorphine, injectable
Description: Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone, liquid oral
Description: Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diacetylmorphine, liquid oral
Description: Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
Study: NCT02232880

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day \[Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day\], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
Study: NCT03811275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality (A) then Task (B)
Description: Participants will use their intact arm to perform virtual reality tasks while perceiving a reflected virtual image of their paretic arm.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task (B) then Virtual Reality (A)
Description: Participants will use their paretic arm to perform real tasks in a structured environment, with a practice and feedback schedule organized by a physical or occupational therapist, or graduate student.
Study: NCT02848443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil hydrochloride (S 95005)
Description: Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
Study: NCT03874260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fenofibrate
Description: statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate vs statin(rosuvastatin 10mg or atorvastatin 10mg or atorvastatin 20mg) + choline fenofibrate placebo / once a day, P.O
Study: NCT00266864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Transdermal System (Androderm 5 mg patch)
Description: Testosterone Transdermal System (Androderm 5 mg patch)
Study: NCT03492008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Nasogastric tube insertion with patient's head in neutral position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contralateral cricothyroid pressure
Description: Cricothyroid pressure is applied externally in the contralateral direction of selected nostril before nasogastric insertion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ipsilateral head turning
Description: Patient's head is turned to the ipsilateral side of the selected nostril before nasogastric tube insertion.
Study: NCT04045418

Intervention type: DEVICE
Intervention: Laser doppler
Description: A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.

Intervention type: DEVICE
Intervention: Laser doppler
Description: A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.

Intervention type: DEVICE
Intervention: Laser doppler
Description: A laser doppler flowmetry will be used to measure the microcirculatory characteristics of meridian phenomena. The probes will be left at relevant measuring sites. Blood flow curve and Perfusion units (PU ) will be recorded constantly.~1. Healthy control group and COPD group The probes will be left at Shenmen (HT7) and Shaohai (HT3) of the Heart meridian, Taiyuan (LU9) and Chize (LU5) of the Lung meridian for 5 minutes.~2. Healthy intervention group Two sessions of moxibustion will be performed in the Heart meridian and Lung meridian successively.
Study: NCT01574833

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed electromagnetic field
Description: PEMF treatment

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: sham treatment
Study: NCT03505710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.
Study: NCT02747979

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hemodialysis only
Description: hemodialysis treatment only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hemodialysis only
Description: hemodialysis treatment only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hemodialysis only
Description: hemodialysis treatment only

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hemodialysis plus hemoperfusion(HA330)
Description: combination of hemodialysis and hemoperfusion (HA330) treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hemodialysis plus hemoperfusion(HA130)
Description: combination of hemodialysis and hemoperfusion (HA130) treatment
Study: NCT03991546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy Delivered via an Automated Mobile Messaging Robot
Description: Mobile messages utilizing the principles of Acceptance and Commitment therapy. These messages were developed in collaboration with a pain psychologist who specializes in treating chronic pain with Acceptance and Commitment therapy. Subjects received twice-daily messages for two weeks following their orthopaedic procedure.
Study: NCT02491359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03344523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron protein succinylate oral solution
Description: Iron protein succinylate oral solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard treatment
Description: standard treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard treatment
Description: standard treatment
Study: NCT01406405

Intervention type: PROCEDURE
Intervention: Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)
Description: Lumbar or cervical fusion

Intervention type: PROCEDURE
Intervention: Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)
Description: Lumbar or cervical fusion
Study: NCT02122601

Intervention type: DRUG
Group type: OTHER
Intervention: LBSA0103 (BDDE cross-linked sodium hyaluronate gel)
Study: NCT01888432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus + reduced tacrolimus
Description: Everolimus was initiated at Week 4 post transplantation. The dose was adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus was reduced to 3-5 ng/mL.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard tacrolimus
Description: Tacrolimus was initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should've been 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
Study: NCT01073501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
Study: NCT04278105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HD-tCES
Description: The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. HD-tCES will be applied for 20 minutes at an intensity of 1.0 mA direct current stimulation and a specific-added waveform each time, 3 times a week, lasting for 4 weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham HD-tCES
Description: The positions of the lesion side primary motor cortex were defined as C3/C4 according to the international 10-20 system of electroencephalograms. Sham HD-tCES will consist of a 5-second ramp up to 1.0 mA direct current stimulation and a specific-added waveform followed immediately by a 5-second ramp down, no current in the middle 19 minutes 40 seconds, and a ramp-up and ramp-down period during the last 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Upper extremity rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
Study: NCT01363765

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xpert MTB/Rif
Description: Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smear microscopy
Description: Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
Study: NCT01552499

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Study: NCT04278105

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Upper extremity rehabilitation
Description: Upper extremity rehabilitation programs will be selected and graded in accordance with each patient's upper extremity function and specific aims of activities of daily living. Upper extremity rehabilitation will be provided for 30 minutes each time, 3 times a week, lasting for 4 weeks.
Study: NCT01930331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemisinin/naphthoquine
Description: Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).~The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet)).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dihydroartemisinin/piperaquine phosphate
Description: Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
Study: NCT04608461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pumpkin seed extract containing cream
Description: Pumpkin seeds extract, white wax, white petrolium, stearyl alcohol
Study: NCT03453372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRgFUS Treatment
Description: Treatment of pain caused by knee osteoarthritis with high-intensity focused ultrasound
Study: NCT02375867

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: Oral administration of 1 mg/Kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: Intravenous injection of 0.8 mg/kg/day
Study: NCT03543813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-2029
Description: CX-2029 Monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-2029
Description: CX-2029 Monotherapy
Study: NCT02625584

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reading Together - Dialogic Reading
Study: NCT03543813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-2029
Description: CX-2029 Monotherapy
Study: NCT01649336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162, MEK inhibitor; oral
Description: multiple dose, escalating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel, mitotic inhibitor; intravenous
Description: multiple dose, single schedule
Study: NCT01219556

Intervention type: DRUG
Intervention: Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)
Description: Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
Study: NCT00738816

Intervention type: OTHER
Group type: OTHER
Intervention: Systematic medication review and advisory notes
Description: Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
Study: NCT03440944

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound Guided Peripheral IV Catheter
Description: Patients randomized to this arm will receive an ultrasound guided peripheral IV catheter.
Study: NCT03453372

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Procedures in the placebo group will be identical to procedures in the active group, except no sonications (ultrasound emission) will be used.
Study: NCT03387111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aldoxorubicin HCl
Description: Aldoxorubicin hydrochloride
Study: NCT03440944

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Midline Catheter
Description: Patients randomized to this group will receive a midline catheter. The catheter is 10cm in length.
Study: NCT03387111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-011
Description: Ad5 \[E1-, E2b-\]-CEA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-021
Description: Ad5 \[E1-, E2b-\]-HER2

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-051
Description: Ad5 \[E1-, E2b-\]-Brachyury vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETBX-061
Description: Ad5 \[E1-, E2b-\]-MUC1
Study: NCT00073840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levalbuterol
Description: * Levalbuterol 90 ųg QID (manufacturing sites A or B);~* Racemic Albuterol 180 ųg QID;~* Placebo QID
Study: NCT03387111

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-4000
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6207
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant CEA proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GI-6301
Description: Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Brachyury yeast proteins

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: haNK for infusion
Description: NK-92 \[CD16.158V, ER IL-2\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Recombinant human anti-PD-L1 IgG1 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Recombinant human anti-VEGF IgG1 monoclonal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: cis-diamminedichloroplatinum(II)
Study: NCT02625584

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reading Together - Shared Reading Control
Study: NCT00910975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peg-interferon-alfa2a (Pegasys)
Description: Peg-interferon-alfa2a 180 µg per week
Study: NCT03387111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 2-\[bis(2-chloroethyl)amino\]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: 5-fluoro-2,4 (1H,3H)-pyrimidinedione

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: L-Glutamic acid, N-\[4-\[\[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl\]amino\]benzoyl\]-, calcium salt

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca\[3,4\]benz\[1,2-b\]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Necitumumab is a recombinant human lgG1 monoclonal antibody.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Stereotactic Body Radiation Therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: N-803
Description: Recombinant human superagonist interleukin-15 (IL-15) complex \[also known as IL-15N72D:IL-15RuSu/IgGI Fe complex1)
Study: NCT01819818

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.